Our drug candidates need further derisking to attract capital. I'm confident phase 2 results will do that.
I don't understand why we couldn't wait for topline data . Management had it on record that funding why sufficient for phase 2 trial. Surely $16M could have gone a long way. Couldn't it?
Ann: Positive Efficacy Data for ATH434 in a Primate Model of PD, page-10
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $10.54K | 2.185M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 83226460 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 20397608 | 18 |
View Market Depth
| Last trade - 10.13am 07/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |